Aclaris Therapeutics Inc ACRS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:01 PM EDT
17.65UNCH (UNCH)
Volume
5,725
Close
17.65quote price arrow down-0.35 (-1.94%)
Volume
432,985
52 week range
9.26 - 19.97
Loading...
  • Open17.94
  • Day High18.37
  • Day Low17.46
  • Prev Close18.00
  • 52 Week High19.97
  • 52 Week High Date09/27/21
  • 52 Week Low9.26
  • 52 Week Low Date01/24/22

Key Stats

  • Market Cap1.177B
  • Shares Out66.67M
  • 10 Day Average Volume0.30M
  • Dividend-
  • Dividend Yield-
  • Beta0.60
  • YTD % Change21.39

KEY STATS

  • Open17.94
  • Day High18.37
  • Day Low17.46
  • Prev Close18.00
  • 52 Week High19.97
  • 52 Week High Date09/27/21
  • 52 Week Low9.26
  • 52 Week Low Date01/24/22
  • Market Cap1.177B
  • Shares Out66.67M
  • 10 Day Average Volume0.30M
  • Dividend-
  • Dividend Yield-
  • Beta0.60
  • YTD % Change21.39

RATIOS/PROFITABILITY

  • EPS (TTM)-1.33
  • P/E (TTM)-13.22
  • Fwd P/E (NTM)-10.87
  • EBITDA (TTM)-83.751M
  • ROE (TTM)-35.47%
  • Revenue (TTM)6.14M
  • Gross Margin (TTM)27.19%
  • Net Margin (TTM)-1,355.98%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date10/31/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Aclaris Therapeutics Inc

There is no recent news for this security.

Profile

MORE
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing drug candidates for immuno-inflammatory diseases. The Company is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. The Company’s drug candidates are Zunsemetinib (ATI-450), ATI-1777 and ATI-2138. The Company’s ATI-450, an investigational...
Christopher Molineaux
Independent Chairman of the Board
Neal Walker
Chief Executive Officer, Co-Founder, Director
Douglas Manion M.D.
President, Chief Operating Officer
Address
640 Lee Rd Ste 200
Wayne, PA
19087-5636
United States

Top Peers

SYMBOLLASTCHG%CHG
DSGN
Design Therapeutics Inc
21.99+0.57+2.66%
RETA
Reata Pharmaceuticals Inc
21.35-2.71-11.26%
VERV
Verve Therapeutics Inc
28.34+1.17+4.31%
CRNX
Crinetics Pharmaceuticals Inc
21.21-0.84-3.81%
ERAS
Erasca Inc
9.50+0.28+3.04%